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ABSTRACT
Transcriptional networks supervising class IIa HDAC
expression are poorly defined. Here we demon-
strate that MEF2D is the key factor controlling
HDAC9 transcription. This control, which is part of
a negative feed-back loop during muscle differenti-
ation, is hijacked in cancer. In leiomyosarcomas the
MEF2D/HDAC9 vicious circuit sustains proliferation
and cell survival, through the repression of the death
receptor FAS. Comprehensive genome-wide studies
demonstrate that HDAC4 and HDAC9 control different
genetic programs and show both specific and com-
mon genomic binding sites. Although the number
of MEF2-target genes commonly regulated is sim-
ilar, only HDAC4 represses many additional genes
that are not MEF2D targets. As expected, HDAC4−/−
and HDAC9−/− cells increase H3K27ac levels around
the TSS of the respective repressed genes. How-
ever, these genes rarely show binding of the HDACs
at their promoters. Frequently HDAC4 and HDAC9
bind intergenic regions. We demonstrate that these
regions, recognized by MEF2D/HDAC4/HDAC9 re-
pressive complexes, show the features of active en-
hancers. In these regions HDAC4 and HDAC9 can dif-
ferentially influence H3K27 acetylation. Our studies
describe new layers of class IIa HDACs regulation,
including a dominant positional effect, and can con-
tribute to explain the pleiotropic actions of MEF2 TFs.
INTRODUCTION
Class IIa HDACs are important regulators of different
adaptive and differentiative responses. During embryonic
development, these deacetylases influence specific differen-
tiation pathways and tissue morphogenesis (1–3). In ver-
tebrates HDAC4, HDAC5, HDAC7 and HDAC9 consti-
tute the class IIa subfamily. Because of the Tyr/His sub-
stitution in the catalytic site, they exhibit a negligible lysine-
deacetylase activity (2,3). However, the deacetylase domain,
through the recruitment of the NCOR1/NCOR2/HDAC3
complex, can influence histones modifications, including
acetylation (4–6). The repressive influence of class IIa
HDACs can also be exploited independently from HDAC3
recruitment. In fact MITR, a HDAC9 splicing variant, can
still repress transcription in the absence of the deacety-
lase domain (7). The amino-terminus of class IIa HDACs
is dedicated to the binding of different transcription fac-
tors (TFs), among which MEF2 family members are the
foremost characterized (3). Overall, class IIa HDACs ge-
nomic activities require their assembly into multiprotein
complexes where they operate as platforms coordinating the
activity of TFs, as well as of other epigenetic regulators (1–
3,8).
These deacetylases are subjected to multiple levels of
regulation. The phosphorylation-dependent control of the
nuclear/cytoplasmic shuttling has been the most com-
monly investigated (3,9). Curiously, although the lineage-
dependent expression is a main feature of class IIa, sig-
nalling pathways and mechanisms controlling their tran-
scription are largely unknown (3). An exception is the mus-
cle tissue. Here HDAC9 transcription is under the direct
control of MEF2D. In this manner, the MEF2D-HDAC9
axis sustains a negative-feedback loop in the transcrip-
tional circuit of muscle differentiation to buffer MEF2D
activities (10). Importantly, in specific cancer types, this
circuit seems to be misused. In pre-B acute lymphoblas-
tic leukaemia MEF2D oncogenic fusions dramatically up-
regulate HDAC9 expression (11,12). Abrogation of the
MEF2D-HDAC9 negative circuit was also observed in
highly aggressive malignant rhabdoid tumor, non-small cell
lung cancer, oral squamous cell carcinoma and leiomyosar-
coma (13). Since the pro-oncogenic roles of class IIa HDAC
have been proved by different studies, understanding the
reasons and the importance of such abrogation is of primary
interest in cancer research (14–18).
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In this manuscript, we have investigated the MEF2-
HDAC axis in cellular models of leiomyosarcoma (LMS).
LMS are rare highly malignant tumors of mesenchymal ori-
gin, with cells presenting features of the smooth muscle lin-
eage (19). We have demonstrated that theMEF2D-HDAC9
axis plays a key role in the maintenance of the transformed
phenotype and deciphered the genomic, epigenomic, and
transcriptomic landscapes under the control of class IIa
HDACs.
MATERIALS AND METHODS
Cell cultures and cytofluorimetric analysis
Leiomyosarcomas cells (LMS), SK-UT-1, SK-LMS-1,
MES-SA and DMR were grown as previously described
(15). HEK-293T and AMPHO cells were grown in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10% FBS. For PI staining, cells were collected and
resuspended in 0.1 ml of 10 g/ml propidium iodide (PI)
(Sigma-Aldrich), in PBS and incubated for 10 min at
RT. After washes, cells were fixed with 1% formaldehyde
(Sigma-Aldrich) and treated with 10 g/ml RNase A. Flu-
orescence was determined with a FACScan™ (Beckman
Dickinson).
CRISPR/Cas9 technology
The generation of HDAC4 and HDAC9 null SK-UT-1
cells was previously described (6). SK-UT-1 cells mu-
tated in the MEF2-binding sites within the HDAC9
promoter were obtained after co-transfection of the
pSpCas9-2A Puro plasmid expressing the two sgRNA
(GGTCGGCCTGAGCCAAAAAT, CTGGACAGCT





10:1). After selections, clones were screened by PCR and
immunoblot. Sanger sequencing was applied for the final
validation.
Immunofluorescence, random cell motility and immunoblot-
ting
Cells were fixed with 3% paraformaldehyde and perme-
abilized with 0.1% Triton X-100. The secondary antibod-
ies were Alexa Fluor 488-, 546- or 633-conjugated anti-
mouse and anti-rabbit secondary antibodies (Molecular
Probes). Actin was labelled with phalloidin-AF546 (Molec-
ular Probes). Cells were imaged with a Leica confocal scan-
ner microscopy SP2. Nuclei were stained with Hoechst
33258 (Sigma-Aldrich). For S phase analysis, cells were
grown for 3 h with 50 M bromodeoxyuridine (BrdU). Af-
ter fixation, coverslips were treated with HCl and processed
for immunofluorescence. For random cell motility measure-
ments, cells were seeded in six-well plates coated with fi-
bronectin and subjected to time-lapse analysis. Images were
recorded every 15 min for 6 h with a Leica AF6000 station.
Time-lapse experiments were analyzedwith theMetamorph
software (Molecular Devices).
Cell lysates after SDS-PAGE and immunoblotting on ni-
trocellulose (Whatman) were incubated with primary an-
tibodies. HPR-conjugated secondary antibodies were ob-
tained from Sigma-Aldrich and blots were developed with
Super Signal West Dura (Pierce), as previously described
(20).
Antibodies and chemicals
The primary antibodies used were anti: MEF2D (BD Bio-
science); MEF2A (C-21), Caspase-3 (E-8) and FAS (M-
20) (Santa Cruz Biotechnology); RAN and Caspase 8
(D35G2) (Cell Signaling Technology); Actin, BrdU, and
FLAG/M2 (Sigma-Aldrich); GFP, HDAC4 and Caspase-
9 (15); HDAC5 (21); H3K27ac (ab4729) and H3K27me3
(ab6002) (Abcam); H3K4me3 (GTX128954, GeneTex).
The anti-HDAC9 antibody was produced in rabbit by in-
jecting a His-tagged fragment of HDAC9 (aa 275–600) ex-
pressed in Escherichia coli. The antiserum was affinity puri-
fied against the same fragment GST-tagged of HDAC9.
The following chemicals were used: Doxorubicin and
Metformin (Alexis); Lapatinib and Imatinib (LC Labora-
tories); MKK2206 and SAHA (Cayman Chemicals); BrdU
(Sigma-Aldrich); FasL (Peprotech).
Plasmid construction, transfection, retroviral and lentiviral
infection, silencing
pLENTI-CRISPR/V2 (Plasmid #52961) and
pSpCas9(BB)-2A-GFP(PX458) (Plasmid #48138) were
from Addgene. pWZL-HYGRO FLIPs FLAG was
obtained by a restriction-based approach from pcDNA3-
FLIPs. pWZL-HYGRO FLAG plasmid was used as
acceptor plasmid and as control for infection. The knock-
down of MEF2D and MEF2A was achieved by using
pLKO.1 shRNAs (TRCN0000015897, TRCN00000274054,
TRCN00000432718, TRCN000005133), as already de-
scribed (6). For the Luc assay on HDAC9 promoter
the 15897 and 432718 shRNAs were selected and used
in consideration of their higher efficiency (6). HDAC9
promoter (6) (bp –1160/+23) activity was measured in
transfected 293-T or SK-UT-1 cells according to the man-
ufacturer (Dual-Glo Luciferase Assay System, Promega)
and expressed as a ratio to the luciferase activity of pRe-
nilla. Transfections, viral infections and siRNA delivery
were done as previously described (20,21). The following






Caspase and Resazurin reduction assays
The caspase activity was evaluated using the Apo-ONE
caspase-3/7 homogeneous assay (Promega). Cells grown in
96-well plates were treated with the different insults and
tested for caspase activity as recommended by the vendor.
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cells were incubated for 150 min. at 37◦C with resazurin so-
lution (0.15mg/ml) (Sigma-Aldrich). The product of reduc-
tion was quantified by using the PerkinElmer EnSpire 2300
Multilabel Reader.
ChIP, library construction, ChIP-seq and NGS data analysis
ChIP was performed as previously described (18). Chro-
matin was immunoprecipitated with 2 g of anti-H3K27ac,
2.5 g of anti-MEF2D, 4 g of anti-HDAC4 and anti-
HDAC9 antibodies or control IgG. Three independent ex-
periments were pulled and 5 ng of total DNA were used
to prepare ChIP-seq libraries, according to TruSeq ChIP
Sample Preparation guide (Illumina). Libraries were se-
quenced on the Illumina HiSeq 2000 sequencer. The qual-
ity of sequencing reads was evaluated using the ShortRead
R/Biocoductor package (23). Sequencing reads fromChIP-
seq experiments were aligned to the NCBI GRCh38 human
reference with Bowtie 2 (24). Peak calling was performed
against input sequences using MACS2 (25). Gene annota-
tion, Venn diagrams and bar plots representing the peak lo-
calization in genomic elements/distance from TSS were ob-
tained using the ChIPseeker R/Bioconductor package (26).
Peak heatmaps and genomic loci visualization were gener-
ated using the gplots, biomaRt and Gviz R/Bioconductor
packages (27–30). H3K27ac signals were normalized using
theMAnormmethod for quantitative comparison of ChIP-
seq data (31).
RNA extraction and quantitative qRT-PCR
Cells were lysed using Tri-Reagent (Molecular Research
Center). 1.0g of total RNAwas retro-transcribed by using
100 units of M-MLV Reverse transcriptase (Life Technolo-
gies) in the presence of 1.6 M oligo(dT) and 4 M Ran-
dom hexamers. qRT-PCRs were performed using SYBR
green technology (KAPA Biosystems). Data were analyzed
by comparative threshold cycle (delta delta Ct Ct) us-
ingHPRT andGAPDH as normalizer. A list of the primers
used for qRT-PCR and ChIP-qPCR is provided in Supple-
mentary Table S1.
RNA expression array and data analysis
Aliquots of RNAs, purified using RNeasy columns (Qia-
gen), were amplified according to the specifications of the
Illumina TotalPrep RNAAmplification Kit (Ambion). Hy-
bridization on Illumina whole-genome HumanHT-12 v 4.0
chip (Illumina), scanning and background subtraction were
done according to the manufacturer’s specification. Fold-
change and P-values for each probe set were calculated
as previously described (18). P-values data were then cor-
rected for multiple hypotheses testing using the Benjamini–
Hochberg methods. Differentially expressed genes (DEGs)
were selected based on fold changes and adjusted P-values
<0.05. Gene set enrichment analysis (GSEA) and the
MSigDB database http://software.broadinstitute.org/gsea/
index.jsp (32,33) were used to investigate statistically rele-
vant biological associations.
Gene lists were analyzed separately using the Ge-
neOntology (BiologicalProcess and ImmuneSystemPro-
cess; Min GO Level = 3 and Max GO Level = 8),
KEGG, WikiPathways, CORUM-FunCat-MIPS, REAC-
TOME Pathways and REACTOME Reactions databases
as source of information. A right-sided hypergeometric test
(corrected using the Benjamini–Hochberg) was applied to
find enriched terms.
Statistics
For experimental data Student t-test was employed.Mann–
Whitney test was applied when normality could not be as-
sumed. P < 0.05 was chosen as statistical limit of signif-
icance. For comparisons between samples >2, the Anova
test was applied coupled to Kruskal–Wallis and Dunn’s
Multiple Comparison Test. We marked with *P< 0.05, **P
< 0.01, ***P < 0.001. Unless otherwise indicated, all the
data in the figures were represented as arithmetic means ±
the standard deviations from at least three independent ex-
periments.
RESULTS
HDAC9 is a MEF2-target gene highly transcribed in
leiomyosarcomas cells
Class IIa HDACs and particularly HDAC5 and HDAC9,
are overexpressed in approximately 30% of leiomyosar-
comas (LMS) (20,34). The mechanisms responsible for
this up-regulation are not defined. The TCGA data anal-
ysis (Figure 1A) shows that in LMS patients the co-
overexpression of one class IIa HDAC and one MEF2 TF
is frequent. In fact, a significant co-occurrence of MEF2D
and HDAC9 overexpression (P-value 0.035, log odds ra-
tio 1427) and a trend of co-occurrence for MEF2A and
HDAC5 mark these patients. ENCODE data evidence
the presence of MEF2 binding sites, which are conserved
through evolution, in the proximal promoter of HDAC9
(Figure 1B). We proved that MEF2D up-regulates the tran-
scription from the HDAC9 promoter in different cell lines
including LMS cells (Figure 1C). SK-UT-1 cells faith-
fully reflect LMS in terms of MEF2D and HDAC9 de-
regulation. Both proteins are highly up-regulated in these
aggressive cells (6). When MEF2D was silenced, HDAC9
expression was down-regulated at the mRNA and pro-
tein levels (Figure 1D, F). By contrast, MEF2A silenc-
ing does not influence HDAC9 levels (Supplementary Fig-
ure S1A, B). Finally, in SK-UT-1 cells transcription from
the HDAC9 promoter was strongly dependent on MEF2D
(Figure 1E).
ChIP experiments demonstrated that MEF2D binds the
promoter of HDAC9 (Figure 1G). MEF2D is required to
sustain an open chromatin status, characterized by high lev-
els of H3K4me3 and H3K27ac, on the HDAC9 promoter
but not on the control TK promoter (Figure 1H and Sup-
plementary Figure S1C). MEF2D down-regulation favors
the appearance of H3K27me3 (Figure 1H and Supplemen-
tary Figure S1C). In summary, MEF2D is a key TF that
boosts HDAC9 transcription in SK-UT-1 cells.
HDAC4 and HDAC9 show different subcellular localizations
in LMS cells
To study the role of class IIa HDACs in LMS, we gener-
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Figure 1. The MEF2D-HDAC9 circuit in leiomyosarcomas. (A) Oncoprint of mRNA expression variations for the indicated MEF2 and class IIa HDACs
family members. Data were obtained from the TCGA database and include RNAseq data of 100 patients with LMS. The heatmap shows the expression
levels (z-score normalized log2 (FPKM) values) andwas generated through cBioPortal (http://www.cbioportal.org). (B) The evolutionary conserved binding
site, validated by ENCODE, for MEF2A (blue) and for MEF2C (red) in the proximal promoter of HDAC9 are shown. (C) Luciferase assay for HDAC9
promoter activity in HEK-293 cells transfected with MEF2D-GFP or GFP and the promoter regions (bp –1160/+23) amplified from IMR90, SK-LMS-1
and SK-UT-1 cells. 3xMEF construct, presenting three binding sites for MEF2, was used as positive control. Data were normalized by co-transfecting
pRenilla and expressed as mean ± S.D., n = 3. (D) mRNA expression levels of the indicated genes, as measured by qRT-PCR, in MEF2D knock-down
cells with respect to control. Two independent shRNA were used. Data are expressed as mean ± S.D., n = 3. (E) Luciferase assay for HDAC9 or control
promoter activities in SK-UT-1 cells silenced for MEF2D expression. Data were normalized by co-transfecting pRenilla and expressed as mean ± S.D., n
= 3. (F) Immunoblot analysis in SK-UT-1 MEF2D knock-down cells, using the indicated antibodies. Actin was used as loading control. (G) Chromatin
was immunoprecipitated from SK-UT-1 cells WT or silenced for MEF2D, using the anti-MEF2D antibodies. Normal rabbit IgGs were used as control.
The HDAC9 promoter region (-758:-528) containing the MEF2 binding sites was amplified. Data are presented as mean ± S.D., n = 4. (H) Chromatin
was immunoprecipitated using the anti-H3K4me3, anti-H3K27ac and anti-H3K27me3 antibodies from SK-UT-1 cells and SK-UT-1 silenced forMEF2D.
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using the CRISPR/Cas9 technology (6). Two different
clones, generated using two different guides, were selected
for each KO. Immunoblot analysis shows that LMS cells
express HDAC9 and high levels of its splicing variant
MITR (Figure 2A). As predicted, in HDAC9 KO cells
both isoforms are absent. Curiously, in HDAC4−/− cells
a different pattern of HDAC9 can be appreciated. Levels
of the full-length HDAC9 are reduced and a shorter iso-
form is increased. Similarly, also the levels of MITR are
augmented. In HDAC9−/− cells, a fast migrating HDAC4
isoform is detectable, which shows a size similar to the
caspase-cleaved fragment of this deacetylase (35) (see be-
low). The levels of HDAC5 are augmented in the two KO
cells, more strongly in HDAC9−/− cells, possibly as part
of a compensatory mechanism. HDAC7 is expressed at ex-
tremely low/undetectable levels in SK-UT-1 cells. Similarly,
MEF2A andMEF2D levels are augmented in the KO cells,
withMEF2A showing a higher increase inHDAC9−/− cells.
These increases correlate with elevated levels of the corre-
sponding mRNAs (Supplementary Figure S3A).
Regulation of class IIa HDACs nuclear-cytoplasmic
shuttling is a key aspect for the control of their repressive ac-
tivities. Immunofluorescence analysis proved that HDAC9
is prevalently nuclear in these LMS cells (Figure 2B). As
a consequence, its localization is not influenced by lepto-
mycin B treatment (Figure 2B). By contrast, HDAC4 shows
a pan/diffused localization, which can be converted into nu-
clear after the inhibition of the CRM1-dependent nuclear
export (Figure 2B). Ran localization was used as counter-
staining. The KOs cells have proved the antibodies speci-
ficity. In summary, while HDAC9 is largely nuclear resident,
HDAC4 is constantly subjected to nuclear/cytoplasmic
shuttling.
Transcriptomes under HDAC4 and HDAC9 regulation in
LMS cells
To investigate the genetic repertoire under the control of
HDAC4 and HDAC9 in LMS, the transcriptome of two
HDAC4−/− clones (26 and 125) and twoHDAC9−/− clones
(167 and D43) generated with independent guide pairs were
compared.
The vast majority of the up- and down-regulated genes
(n = 566 and n = 533, respectively), were shared be-
tween the two HDAC4−/− clones (Figure 3A). By con-
trast, HDAC9−/− clones have much less commonly regu-
lated genes (n = 130 up- and n = 71 down-regulated) and
a consistent number (n = 192 up- and n = 159 down-
regulated) were clone-specific (Figure 3B, Supplementary
Tables S2, S3 and Figure S2).
In order to define a common gene signature, we com-
pared the lists of up- and down-regulated genes between
HDAC4−/− andHDAC9−/− cells. Twenty nine induced and
21 repressed genes represent the common signature of the
two class IIa HDACs (Figure 3C). This result suggests that
the two HDACs play distinct roles in LMS cells.
Since class IIaHDACs are well-known repressors of tran-
scription, we focused the attention on transcripts whose lev-
els increased after the knock-outs. To further confirm the
specific activities of the two HDACs, we compared the lev-
els of genes up-regulated in HDAC4−/− cells with those in
Figure 2. Characterization of SK-UT-1 cells knocked-out for HDAC4 and
HDAC9. (A) Immunoblot analysis of HDAC9,MITR, HDAC4, HDAC5,
MEF2A and MEF2D in SK-UT-1 cells WT and in two KO clones for
HDAC4 (125 and 26) and HDAC9 (167 and D43). Asterisk points to a
non-specific band. Actin was used as loading control. (B) Immunofluores-
cence analysis in SK-UT-1WT,HDAC4−/−, HDAC9−/− cells stainedwith
the indicated antibody.Where indicated, cells were treated for 2 hwith Lep-
tomycin B (Lept. 50 ng/ml) to inhibit the nuclear export. The anti-RAN
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Figure 3. HDAC4 and HDAC9 regulate different patterns of genes, only partially overlapping. (A) Venn diagrams showing the number of transcripts
commonly and differentially up-regulated or downregulated between the two clones of HDAC4−/− cells. (B) Venn diagrams showing the number of
transcripts commonly and differentially up-regulated or downregulated between the two clones of HDAC9−/− cells. (C) Venn diagrams showing the
number of transcripts commonly and differentially up-regulated or downregulated among the different clones of HDAC4−/− and HDAC9−/− cells. (D)
Heatmap of the 566 significantly up-regulated genes inHDAC4−/− cells and their expression levels inHDAC9−/− cells. In the heatmap genes up-regulated
are shown in green and down-regulated in blue, as fold changes. (E) Heatmap of the 130 significantly up-regulated genes in HDAC9−/− cells and their
behavior in HDAC4−/− cells. In the heat map genes up-regulated are shown in green and down-regulated in blue, as fold changes. (F) Bar plots of the
Cytoscape-ClueGOmost significantly enriched functional terms according to the GO: Biological Process, Reactome or WikiPathways databases. Analysis
were performed for the indicated groups of up-regulated genes, retaining the top 3 terms defined by the two most informative functional databases. (G)
Pie charts illustrating the dependency on MEF2 of the genes up-regulated in HDAC4−/− and HDAC9−/− cells. The dependency on MEF2 was scored
by looking at the genes affected by MEF2A/D knock-down (6). (H) Effect of MEF2A and MEF2D silencing on the gene lists associated with the most
significantly enriched functional terms of the Cytoscape-ClueGO analysis as shown in (A) in SK-UT-1 HDAC4−/− cells. The dependency on MEF2 was
expressed as percentage. (I) Effect of MEF2A and MEF2D silencing on the gene lists associated with the most significantly enriched functional terms of
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HDAC9−/− cells and vice versa. Heatmaps show that al-
though a group of genes was similarly up-regulated by the
knock-out of the two HDACs, many genes were specific for
each HDAC, as they were unperturbed in the other KO or,
in some instances, repressed (Figure 3D and E). qRT/PCR
analysis on a panel of these differentially regulated genes
further validated these results (Supplementary Figure S3A).
The genetic programs regulated by HDAC4 and HDAC9
We used the Cytoscape plugin ClueGO (36,37) to under-
stand the functions of genes up-regulated in HDAC4−/−
and HDAC9−/− cells, as well as of genes induced in both
conditions. As expected, the most significantly enriched
functional terms differ from HDAC4 and HDAC9 (Fig-
ure 3F). HDAC4-repressed genes are involved in the ox-
idative stress response, proliferation and programmed cell
death. By contrast, HDAC9 repressed genes include nega-
tive regulators of cell migration/locomotion and regulators
of actin cytoskeleton. Interestingly, death receptor signaling
emerged as a pathway under HDAC9 influence. A common
genetic program regards the mineral absorption.
In order to identify genes under the influence of the
MEF2-HDAC axis, we compared the lists of genes up-
regulated in HDAC4−/− and HDAC9−/− cells with genes
that are repressed by MEF2A and MEF2D in the same
cells (6). Figure 3G highlights such overlaps, indicating a
similar and strong contribution of these TFs to HDAC9-
mediated repression. Although themajority of theHDAC4-
repressed genes are not under the influence of MEF2A or
MEF2D, the absolute number of MEF2A/D target genes
is similar to HDAC9. Furthermore, within the HDAC4-
repressed genes, MEF2A influence is more pronounced
compared to MEF2D. This observation was confirmed by
GSEA (Genes Set Enrichment Analysis). Here significant
enrichmentswere obtained onlywhen the comparisonswere
performed between HDAC9 and MEF2A or MEF2D reg-
ulated genes (Supplementary Figure S3B).
Subsequently, we wondered to what extent MEF2-
HDAC co-targets could recapitulate the previously identi-
fied biological functions associated with genes repressed by
HDAC4 or HDAC9. Figures 3H/I summarizes the number
(n) of genes associated with each enriched term, the per-
centage of genes that are also MEF2A or MEF2D targets,
the percentage of those in common between MEF2A and
MEF2D (MEF2A &MEF2D) and the percentage of those
that are targets of at least oneMEF2 (MEF2A +MEF2D).
Finally, we used a right-sided Fisher’s exact test to deter-
mine the probability that each biological function was sig-
nificantly enriched in one of the HDAC/MEF2 co-target
subsets with respect to the corresponding list of upregu-
lated genes in HDAC4−/− or HDAC9−/− cells. Firstly, this
allowed the identification of ‘response to oxygen-containing
compound’ and ‘programmed cell death’ as terms enriched
in both MEF2A (P-value = 7e–03 and P-value = 7e–04,
respectively) and MEF2D targets common to HDAC4 (P-
value = 7.5e–03 and P-value = 5.3e–03, respectively). We
also defined ‘negative regulation of locomotion’ as specifi-
cally enriched (P-value = 4.6e–02) in the HDAC9/MEF2A
targets subset, representing the only HDAC9-related bio-
logical process showing specificity for one of the twoMEF2
regulators.
In summary our data demonstrate that different MEF2-
HDAC complexes can regulate distinct gene-networks.
Mapping the genomic regions bound by HDAC4, HDAC9
and MEF2D
ChIP-seq experiments were performed to investigate, at a
genomic level, HDAC4 and HDAC9 binding in relation
to MEF2D. As expected from the transcriptomic analysis,
HDAC4 shows a higher genomic binding (n = 7732) com-
pared toHDAC9 (n= 1257), whileMEF2Dpeaks are 2214,
in agreement with previous studies (38). 68% of MEF2D
peaks contains at least a MEF2 binding sites (Supplemen-
tary Table S4). By comparing the binding locations, 45% of
MEF2D peaks co-localize with HDAC4, HDAC9 or both
(Figure 4A). In particular, 56% of these events are in com-
monwithHDAC4 andHDAC9, 43% areMEF2D/HDAC4
specific and only 1.2% are MEF2D/HDAC9 specific.
HDAC4 displays a substantial MEF2D-independent activ-
ity as 82% of its peaks are bound neither by MEF2D nor
by HDAC9. On the contrary, HDAC9 specific peaks are
less frequent (20%). DNA motif analysis on the HDAC4-
specific peaks showed an enrichment for SMAD3 and
CENPB binding motifs. When the same analysis was per-
formed on HDAC4-specific peaks localized in H3K27ac
enriched regions, BACH2 and ZNF384 showed the high-
est enrichments (Supplementary Figure S4). The ChIP-seq
data for MEF2D, HDAC4, HDAC9 and the variations in
H3K27ac were confirmed by ChIP-qPCR for 11 distinct
genomic regions (Supplementary Figure S5). Overall, the
analysis of the genomic binding sites confirms the different
activities of the twoHDACs, as emerged from the transcrip-
tomic analysis.
The majority of HDAC4 and HDAC9 peaks localize in
intergenic regions, (68% and 76%, respectively), as previ-
ously observed for other class IIa HDACs (18,39,40). By
contrast only 36% of MEF2D peaks map in intergenic re-
gions while 27% are in promoter regions (Figure 4B). In-
terestingly, MEF2D peaks localization undergoes signif-
icant changes when associated with common binding of
HDAC4/HDAC9. In these cases 64% occur in intergenic,
14% in introns and only 18% in promoter regions. This re-
localization seems to only partially depend on the presence
of HDAC4 alone, since MEF2D/HDAC4 common map-
ping is 47% intergenic, 29% intronic and 17% in promoter
regions. To further evaluate the chromatin status around
these peaks, we mapped the H3K27 acetylation either as a
perfect overlap (min. 1 bp in common) or in a 2 kb interval
from the peak summit (Figure 4C). Overall, the presence of
HDAC4 frequently correlates with an open chromatin sta-
tus, while HDAC9 peaks are commonly confined in regions
marked by poor H3K27 acetylation. These correlations are
MEF2-independent. In general, the co-presence ofMEF2D
increases H3K27 acetylation incidence (Figure 4C).
It is plausible that the genomic binding sites of the two
class IIa HDACs and possibly of MEF2D, within the reg-
ulative elements of the genes up-regulated after the KO of
HDAC4 and HDAC9, may influence their epigenetic sta-
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Figure 4. Defining the genomic binding sites and influences of MEF2D, HDAC4 and HDAC9 on H3K27ac. (A) Venn diagrams showing the overlaps
between the MACS2-definedMEF2D, HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. (B) Genomic distribution of the MACS2-defined
MEF2D, HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. (C) Proximity, expressed as percentage, of H3K27ac marks to the MEF2D,
HDAC4 and HDAC9 ChIP-seq enriched peaks in SK-UT-1 cells. The minimum distance is 0bp (overlapping) and 1kbp, respectively, for the left and right
panel. (D) Heatmaps showing the differences inH3K27ac distribution betweenHDAC4−/− andHDAC4+/+ orHDAC9−/− andHDAC9+/+ SK-UT-1 cells.
The displayed regions are located ±3kb around the TSS of a subset of 475 microarray-defined HDAC4 repressed genes (left panel) and of 118 microarray-
defined HDAC9 repressed genes (right panel). Binding peaks for MEF2D, HDAC4 and HDAC9 in the same regions are also provided. The differences in
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evaluated variations of the H3K27ac status around the TSS
(-/+3kb) of these genes. In the same regions, we also in-
vestigated the presence of MEF2D, HDAC4 and HDAC9
peaks. We excluded from the analysis transcripts with un-
defined functional annotations, thus resulting in 475 genes
for HDAC4−/− and 118 genes for or HDAC9−/− cells.
The levels of H3K27ac were augmented around the
TSS of several genes up-regulated in HDAC4−/− and
HDAC9−/− cells. This increase was evident also in regions
more distal with respect to the TSS (Figure 4D). Frequently,
acetylation spreading emerged as a consequence ofHDAC4
and HDAC9 deletions.
Fourteen genes are characterized by HDAC4 binding
within 3 kb from the TSS and six of them also show co-
binding withMEF2D. Among these six genes,ARMC4 and
MPP7 evidence multiple binding events for MEF2D and
HDAC4 (Figure 4D). These two genes are marked by in-
tense spreading ofH3K27ac in the absence ofHDAC4. Sur-
prisingly, peaks for HDAC9were not found around the TSS
of genes up-regulated in knocked-out cells, even though for
4 genes (CXCL1, ENC1, PLK2 and SORT1)MEF2D bind-
ing was observed.
Next, we expanded the analysis up to ±30 kb from the
TSS to find evidence of distal regulative elements. The in-
crease of H3K27ac and the spreading effects elicited by the
absence of the two HDACs was confirmed (Figure 5A).
ARMC4, MKX, MPP7, NFIB, ROR1, ZNRF3 are among
the most evident examples of this behavior in the absence of
HDAC4. CXCL1, CXCL8/IL8 and SMAD3 in the case of
HDAC9 absence. Importantly, CXCL1 and IL8 are among
the highest up-regulated genes inHDAC9−/− cells (Supple-
mentary Table S2).
Twenty five genes show HDAC4 binding within 30kb
from the TSS and frequently with multiple binding events.
Peaks for HDAC9 were again rare, with only RAB31 with
a positive hit. MEF2D genomic binding was found in 28
genes up-regulated in HDAC4−/− cells, of which seven
shared with HDAC4 and in eight genes up-regulated in
HDAC9−/− cells (Figure 5A).
HDAC4 and HDAC9 regulate H3K27ac levels in regulative
regions distal from the TSS
The previous analysis has revealed that, although changes
in H3K27ac are prominent in regions around the TSS
of genes up-regulated after the KO of the two HDACs,
only a fraction of these genes displays the binding of
HDAC4 (5,3%) and rarely of HDAC9 (0.8%). Certainly,
some of these genes could be indirect target of the deacety-
lases. However, since several HDAC4 and HDAC9 peaks
were found in the intergenic regions, we hypothesized that
HDAC4 and HDAC9 in particular, could preferentially in-
fluence gene expression from distal regulative elements such
as enhancers.
To explore this possibility, we investigated the variations
of H3K27ac status after the knock-out of the two HDACs,
at the distal regions marked by the co-presence of MEF2D,
HDAC4 and HDAC9 peaks (Figure 4A; n= 510). Through
this strategy we should identify the functional/active distal
regulative regions of MEF2D target genes.
Approximately 42% of these common peaks lie in H3K27
acetylated regions. 57% of these acetylated regions are
found away from a TSS (>30 kb from the TSS).
Next, we investigated whether some of these distal re-
gions showed HDAC4 or HDAC9 dependent regulation
of H3K27ac levels. Three different groups of peaks can
be identified (Figure 5B). A first group comprises com-
mon peaks that do not show strong variations in rela-
tive H3K27ac fold increases, after the knock-out of both
deacetylases (gray dots). A second group of common
peaks shows increases in relative H3K27ac, which are more
marked in the absence of one of the two deacetylases, more
frequently in HDAC4−/− cells. The third group comprises
H3K27ac peaks that appeared exclusively enriched after the
knock-out of either HDAC4 or of HDAC9.
Within these distal regions differentially modulated by
the two class IIa HDACs, we could expect to find regulative
elements that orchestrate the expression of genes differen-
tially regulated by HDAC9 and responsible for the different
impact on the proliferation of SK-UT-1 cells.
Chromosome conformation capture (3C) assay, com-
bined with Next Generation Sequencing (Hi-C) can pro-
vide a global view of all chromosomal interactions across
the genome and maps Topologically Associated Domains
(TADs) (41,42). Within these domains distal regulative re-
gions can be identified. A distal intergenic region, where
H3K27ac was modulated by HDAC9, is located almost
100kb downstream from ARHGEF28 locus. To understand
whether it could act as a distal enhancer, we compared our
ChIP-seq data to available Hi-C data obtained from the
IMR90 cell line (43).
Figure 6 shows that a region, marked by multiple bind-
ing sites for MEF2D, HDAC4 and HDAC9 dramatically
increases H3K27ac acetylation levels only after the knock-
out of HDAC9. Hi-C data indicate that this region lies
within a defined TAD and that, through chromatin loop-
ing, it could act distally to influence a region close to the
TSS of ENC1. As a matter of fact, the ablation of HDAC9
augments H3K27ac levels in the proximity of ENC1.
Overall this analysis suggests that an intergenic region,
where H3K27ac acetylation is modulated by HDAC9,
could act as distal regulative region (enhancer) for the
ENC1 gene. The detection of eRNAs in the same region reg-
ulated by HDAC9, as defined by SlideBase – FANTOM5
Human Enhancers Selector, further supports this possibil-
ity (44). Importantly, the ENC1 transcript is specifically up-
regulated in HDAC9−/− cells (Supplementary Figures S3B
and S5).
Another example of HDAC9-controlled, distal regulative
region is represented by the intragenic locus of INSYN2B,
which perfectly superimposes to a sub-TAD characterized
by the presence of eRNAs (Supplementary Figure S6A).
Finally, an example of a distal regulative region under the
specific influence of HDAC4 is represented in Supplemen-
tary Figure S6B. This regulative intergenic region is located
∼35 kb upstream from the SLC8A1 locus.Within the TAD,
binding of MEF2D, HDAC4 and HDAC9 can be found.
In this case, however, it is the KO of HDAC4 that causes
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Figure 5. Impact ofHDAC4 andHDAC9 onH3K27 acetylation at genomic regions distal from the TSS. (A) Heatmaps showing the differences inH3K27ac
distribution betweenHDAC4−/− andHDAC4+/+ orHDAC9−/− andHDAC9+/+ SK-UT-1 cells. The displayed regions are located±30kb around the TSS
of a subset of 475 microarray-defined HDAC4 repressed genes (top panel) and of 118 microarray-defined HDAC9 repressed genes (mid panel). Binding
peaks for MEF2D, HDAC4 and HDAC9 in the same regions are also provided. The differences in mRNAs levels are indicated by the heatmaps at the right
side. (B) Acetylation status of MEF2D/HDAC4/HDAC9 co-localizing peaks. Distances from the TSS of the closest coding genes are shown. The increase
of the relative H3K27ac signal after the knock-out of HDAC4 (orange) or HDAC9 (light blue) is indicated. H3K27ac peaks that are exclusively enriched
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Figure 6. Example of a distal regulative region under HDAC9-specific regulation. Detailed view of the MEF2D, HDAC4, HDAC9 and H3K27ac tracks
at the ARHGEF28 locus. H3K27ac normalized tracks are shown for WT, HDAC4−/− and HDAC9−/− SK-UT-1 cells. Gene structure and chromosomal
location are shown, with the red boxes highlighting the presence of enhancer RNAs. The boxes (light blue) evidence the chromatin looping between the
enhancer, under specific regulation of HDAC9 and the promoter of ENC1 whose expression is specifically up-regulated inHDAC9−/−cells. Hi-C data (43)
were used to represent the TADs within the ARHGEF28/ENC1 locus (http://promoter.bx.psu.edu/hi-c/view.php).
HDAC9 influences actin cytoskeleton organization, cell
spreading and motility
The gene expression studies discovered a role of HDAC9
as a coordinator of actin-cytoskeleton organization, cell
adhesion and migration. We proved the relevance in vivo
of this result by comparing the actin cytoskeleton among
the different engineered LMS cell lines. SK-UT-1 wt and
HDAC4−/− cells show a similar phenotype. Cells are bipo-
lar and scattered. Accumulation of F-actin is well evi-
dent in specific localizations at the cell periphery, indica-
tive of membrane ruffles, filopodia and lamellipodia (Fig-
ure 7A). In HDAC9−/− cells, these structures are much
less evident. Cells establish stable contacts resembling ep-
ithelial colonies. We also compared the mitochondrial net-
work using an antibody against DIABLO. Although mito-
chondria were highly fragmented in SK-UT-1 cells, in wt
andHDAC4−/− cells they cluster in the perinuclear regions
whereas in HDAC9−/− cells they are distributed through-
out the cytoplasm (Figure 7A). Quantitative morphome-
tric analysis was performed to compare the spread area
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Figure 7. HDAC9 controls spreading andmotility in LMS cells. (A) Confocal images of the indicated LMS cell lines stained for actin (red), using phalloidin
and DIABLO (green), by immunofluorescence to visualize mitochondria. Bar 50 m. (B) Dot plot representing the spread area of the indicated SK-UT-1
cells. Themedian and the first and third quartiles are indicated; n> 25. (C) Dot plot representing themean speed of the indicated SK-UT-1 cells. Time-lapse
experiments were performed over a period of 6 h. The median and the first and third quartiles are indicated n > 134. (D) Dot plot representing the mean
speed of the indicated SK-UT-1 cells. Time-lapse experiments were performed over a period of 6 hours. The median and the first and third quartiles are
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rescence studies, the spreading was markedly increased in
HDAC9−/− cells (Figure 7B).We also performed time-lapse
studies to compare the random cell motility of the different
cell lines. HDAC9−/− but not HDAC4−/− cells are charac-
terized by a dramatically reduced random cell motility (Fig-
ure 7C, D). Overall these studies demonstrate that HDAC9,
by repressing the expression of cytoskeletal components,
controls cell adhesion, morphology and motility.
HDAC9 sustains cell survival by repressing FAS expression
The transcriptomic studies indicate that HDAC9 could re-
press apoptosis and particularly the activation of the ex-
trinsic apoptotic pathway (Figure 3I). FAS emerged as a
gene specifically up-regulated in HDAC9−/−cells. Analysis
of Hi-C data shows that the FAS locus is embedded within
a subTAD adjacent to the subTAD containing the ACTA2
locus, which is transcribed in the opposite orientation. In-
terestingly, a specific ACTA2 isoform share with FAS the
promoter region (Figure 8A). The ChIP-seq did not iden-
tify peaks for MEF2D and HDAC9 within the FAS lo-
cus. Despite this, H3K27 acetylation is clearly augmented
around the TSS and throughout the first intron of FAS,
in the absence of HDAC9. Similarly a downstream inter-
genic region (approx. 40kb from the FAS TSS) is highly
acetylated in HDAC9−/− cells. Interestingly, Hi-C data in-
dicate that this intergenic region can make contact with the
FAS promoter. H3K27 acetylation in HDAC9−/− cells was
augmented also at the ACTA2 locus (Figure 8A). We vali-
dated the contribution ofHDAC9 in the control of FAS and
ACTA2 mRNA levels by qRT-PCR. As expected, FAS and
ACTA2 expression was up-regulated in HDAC9−/− cells
(Figure 8B). Up-regulation of the FAS protein was also ver-
ified by immunoblot (Figure 8C).
Overall these data suggest that HDAC9 can sustain
SK-UT-1 transformation by repressing the extrinsic apop-
totic pathway. To prove this hypothesis, we analyzed the
proliferative features of the different engineered SK-UT-1
cells. HDAC9 absence marginally reduced the percentage
of cells in S phase. HDAC4−/− cells did not show overt
defects (Supplementary Figure S7A). Time-course experi-
ments showed that HDAC4−/− cells have a partial prolifer-
ative deficit, whereas proliferation of HDAC9−/− cells was
dramatically impaired (Supplementary Figure S7B) and
marked by an increased level of cell death. This low con-
stitutive activation of the apoptotic machinery was con-
firmed by theCaspase-9 andCaspase-3 processing observed
in the absence of apoptotic insults (Supplementary Fig-
ure S7C). When the different LMS cells were grown with-
out serum, cell death was dramatically induced in the ab-
sence of HDAC9 (Supplementary Figure S7D). Finally, we
compared the proliferation of the different SK-UT-1 cells
when incubated with different pro-apoptotic drugs includ-
ing: tyrosine-kinase, HDACs, isopeptidases (22) andAkt in-
hibitors or metmorfin.With the exclusion of the two TK in-
hibitors, only inHDAC9−/− cells all drugs showed a signif-
icant stronger anti-proliferative outcome (Supplementary
Figure S7E). As expected, apoptosis elicited by FAS lig-
and (FASL) was clearly augmented inHDAC9−/− SK-UT-
1 cells (Figure 8D). In vivo, analysis of TCGA data on
leiomyosarcomas showed low levels of FAS mRNA and a
significant anti-correlation between the FAS and HDAC9
mRNA levels (Figure 8E).
The extrinsic apoptotic pathway is activated in the absence of
HDAC9
To prove the involvement of the extrinsic pathway we ex-
pressed the inhibitor of DISC activation FLIPs, the short
isoform of CFLAR/FLIP (45). FAS-induced caspase ac-
tivation was strongly attenuated in the presence of FLIPs
(Figure 8F). Importantly, also the increase of caspase activ-
ity observed in the KO cells in the absence of added apop-
totic insults, was blunted by FLIPs (Figure 8F). Next, we
evaluated the percentage of cell death in untreated cells. The
increase of cell death observed in the HDAC9−/− cells was
completely abrogated by the presence of FLIPs (Figure 8G).
To exclude that the HDAC9-dependent regulation of
FAS levels was a peculiar aspect of SK-UT-1 cells, we ana-
lyzed a panel of LMS cells for HDAC9 expression. HDAC9
levels were abundant also inDMRcells but not in SK-LMS-
1 and MES-SA uterine sarcoma cells (Supplementary Fig-
ure S8A). When HDAC9 was downregulated by two dif-
ferent siRNAs in DMR cells, FAS, ACTA2 and IL8 levels
were all augmented (Supplementary Figure S8B). The up-
regulation of these genes was not observed after HDAC4
silencing. In agreement with SK-UT-1 cells, apoptosis was
increased after HDAC9 silencing also in DMR cells (Sup-
plementary Figure S8C). We also investigated whether an
anti-correlation between class IIa HDACs and FAS levels
could be observed in leiomyosarcomas in vivo. Supplemen-
tary Figure S8D shows that a significant anti-correlation
with FAS expression in LMS involves also HDAC5, in ad-
dition to HDAC9.
We also investigated whether HDAC9 absence increased
the apoptotic susceptibility of SK-UT-1 cells to different
apoptotic insults such as: DNA damage (doxorubicin), Akt
inhibition (MKK2206) and the proteotoxic stressor G5
(Figure 8H). Only apoptosis triggered by doxorubicin and
G5 was potentiated by HDAC9 deletion. This increase was
largely suppressed by the presence of FLIPs, thus suggesting
an involvement of the extrinsic pathway. Analysis of caspase
activation confirmed that the up-regulation of the extrinsic
pathway characterizes the increased apoptotic susceptibil-
ity of HDAC9−/− cells in response to doxorubicin (Figure
8I).
Deletion of the MEF2-binding sites in the HDAC9 promoter
recapitulates the knock-out of HDAC9
Our manuscript opened with the demonstration that
MEF2D is the critical TFs involved in the up-regulation of
HDAC9. Subsequently, we proved thatHDAC9 plays a crit-
ical role in FAS expression and in the regulation of SK-UT-
1 survival. To conclude our study we needed to demonstrate
that the abrogation of the vicious loop between MEF2D
andHDAC9 suppresses cell proliferation, up-regulates FAS
expression and triggers apoptosis.
To this purpose we used the CRISPR/Cas9 technology
to mutagenize the MEF2 binding sites in the HDAC9 pro-
moter (Figure 9A). ChIP experiment demonstrated the ab-
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Figure 8. HDAC9 promotes cell survival by repressing FAS transcription. (A) Genomic view of the ACTA2/FAS locus on chromosome 1 (GRCh38).
Detailed view of H3K27ac normalized tracks (green) for WT, HDAC4−/− and HDAC9−/− SK-UT-1 cells. The boxes (light blue) evidence the chromatin
looping between a distal regulative element and the FAS promoter. Hi-C data were used to define the TADs within the FAS locus. (B) mRNA expression
levels of ACTA2, FAS and GAPDH, as measured by qRT-PCR. Data are presented as mean ± S.D relative to wild-type SK-UT-1 cells, n = 3. (C) Im-
munoblot analysis of FAS levels in the indicated SK-UT-1 clones. Actin was used as loading control. (D) Histogram representing the percentage of PI
positivity in the indicated SK-UT-1 cells, treated with 25 and 50ng/ml of FASL Data are presented as mean ± S.D. n= 3. (E) Scatter dot plot representing
the z-scores of FAS mRNA levels in individual TCGA tumors (n = 100) divided in two classes accordingly to HDAC9 levels. (F) Histogram representing
the percentage of PI positivity in the indicated SK-UT-1 cells, expressing or not FLIPs and treated for 24 hours with 25ng/ml FASL. Data are expressed
as mean ± S.D. n = 3. (G) Caspases activation (DEVDase activity) in the indicated SK-UT-1 cells, expressing or not FLIPs and treated for 24 hours with
25ng/ml of FASL. Data are expressed as mean ± S.D. n = 3. (H) Histogram representing the percentage of PI positivity in the indicated SK-UT-1 cells,
expressing or not FLIPs. Data are expressed as mean ± S.D. n = 3. (I) Caspases activation (DEVDase activity) in the indicated SK-UT-1 cells, expressing
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Figure 9. MEF2D regulative elements in the HDAC9 promoter are required for HDAC9 overexpression, FAS silencing and cell survival (A) Scheme
of the CRISPR-mediated mutagenesis of the two MEF2-binding sites in the HDAC9 promoter (B) Chromatin was immunoprecipitated from SK-UT-1
cells WT or mutagenized in the 2 MEF2D binding sites, using anti-MEF2D antibody. Normal rabbit IgGs were used as control. The HDAC9 promoter
region containing the MEF2 binding sites was amplified. Data are presented as mean ± S.D., n = 3. (C) Chromatin was immunoprecipitated using the
anti-H3K4me3, anti-H3K27ac and anti-H3K27me3 antibodies from SK-UT-1 cells WT or mutagenized in the 2 MEF2D binding sites Data are presented
as mean and standard error. n = 3. (D) Relative mRNA expression levels of GAPDH and HDAC9, as measured by qRT-PCR in WT and SK-UT-1 cells
with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Data are presented as mean ± S.D. n = 3. (E) Immunoblot analysis of HDAC9,
FAS, Caspase-8 and Actin in SK-UT-1 cells WT and with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Actin was used as loading
control. Asterisks point to non-specific bands, arrowhead to the caspase-8 cleaved form. (F) Relative mRNA expression levels of GAPDH, IL8, FAS and
ACTA2, as measured by qRT-PCR in WT and SK-UT-1 cells with mutated MEF2 binding sites in the HDAC9 promoter (MEF2). Data are presented
as mean ± S.D. n= 3. (G) Dot plot representing the spread area of the indicated SK-UT-1 cells. The median and the first and third quartiles are indicated.
n>70. (H) Histogram representing the doubling time of the indicated SK-UT-1 cells over a period of three days in culture. Data are presented as mean ±
S.D. n= 3. (I) Histogram representing the percentage of PI positivity in the indicated SK-UT-1 cells, growing in the absence of any added apoptotic insult.
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neered SK-UT-1 cells (MEF2) (Figure 9B). As a conse-
quence, epigenetic markers of open and active chromatin
are reduced (H3K27ac and H3K4me3) while marker of
closed/repressed chromatin (H3K27me3) appeared once
MEF2 binding site were removed from the HDAC9 pro-
moter. HDAC9 mRNA levels were dramatically decreased
(Figure 9C). Immunoblot analysis confirmed the strong
downregulation of HDAC9 expression, the concomitant
up-regulation of FAS and the activation of Caspase-8 (Fig-
ure 9D). Similarly to FAS, other HDAC9 target genes (IL8
and ACTA2) were up-regulated at the mRNA level when
the MEF2 binding sites in the HDAC9 promoter were mu-
tagenized (Figure 9E). Finally, cell spreading, growth arrest
and cell death were all up-regulated in SK-UT-1 cells with
mutated HDAC9 promoter.
In summary, abrogation ofMEF2 binding at theHDAC9
promoter mirrors the effect ofHDAC9 deletion on SK-UT-
1 cells survival.
DISCUSSION
Dysregulations of class IIa HDACs expression have been
reported in different tumors (1,3,6,13,46). How these al-
terations influence the epigenetic plasticity of cancer cells
is still unknown. In this manuscript we have investigated
the altered expression and dissected the functions of class
IIa HDACs in LMS. These tumors are considered ge-
netically complex soft tissue sarcomas, with a high mu-
tational burden and a complex karyotype with several
losses, gains and amplifications (19,47). Alterations in the
PI3K/AKT/PTEN pathway, deletions of the tumor sup-
pressors TP53 and RB1 and mutations in ATRX and
MED12 (34,48,49) are frequent in LMS. Up-regulation of
miR-143 and miR-145 and low expression of inflamma-
tory response genes are also common in LMS (34). Ap-
proximately 30% of LMS express high levels of a class IIa
HDACs, and of HDAC9 in particular (6).
We have demonstrated that the increased expression of
HDAC9 stems from an alteration of the MEF2-HDAC
feed-back loop. Silencing of MEF2D causes a parallel
downregulation of HDAC9 levels and it is coupled to
the appearance of a repressive epigenetic state at its pro-
moter. Furthermore, the CRISPR-mediated deletion of the
MEF2D binding sites in the HDAC9 promoter switches off
HDAC9 transcription and perfectly recapitulates the prolif-
erative defects of SK-UT-1 cells knocked out for HDAC9.
Our in vitro studies find substantiation in vivo. In LMS
patients the high levels of HDAC9 are significantly corre-
latedwith high levels ofMEF2D expression. A similar alter-
ation in the MEF2-class IIa HDACs loop could be respon-
sible for the overexpression ofHDAC5. In this caseMEF2A
seems to be involved.Dysfunctions of theMEF2D-HDAC9
circuit might be common to other tumor types (50). For
example in pre-B acute lymphoblastic leukemia, character-
ized by MEF2D translocations, HDAC9 is frequently up-
regulated (11–13).
Three important questions still deserve specific answers:
i) which is themechanism that up-regulatesMEF2D expres-
sion in LMS? ii) why does not the MEF2D-HDAC9 com-
plex repress HDAC9 transcription, by binding the HDAC9
promoter? iii) why is the relationship between MEF2D and
HDAC9 so exclusive? Does HDAC9 play a different epige-
netic role with respect to the other class IIa HDACs?
We do not have an answer to the first question. However,
by defining the genomic binding sites for MEF2D, HDAC4
and HDAC9 we provide some cues to the others points.
Class IIa HDACs have been described as tissue specific
deacetylases (1–3,46). Certain phenotypes, observed after
members specific knock-outs in mice or ablation in hu-
man cells, have been explained as the consequence of their
lineage-dependent expression (6,18,21,51–54). Our study
demonstrates that further levels of complexity do exist.
The first level concerns the genomic bindings. HDAC4 and
HDAC9 share several genomic binding sites but HDAC4,
in particular, binds many additional regions, which possi-
bly escape a HDAC9-dependent regulation.
The second level of complexity concerns MEF2D. This
important class IIa HDACs partner can assemble onto spe-
cific genomic regions both the HDAC4 and the HDAC9
repressive complexes, while in other regions only a spe-
cific repressive complex is recruited, most frequently con-
taining HDAC4 rather than HDAC9. Through the selec-
tive recruitment of a specific HDAC or a combination of
more HDACs, MEF2 can monitor different patterns of
gene expression, as verified by the transcriptomic analy-
sis and proved by the different genetic programs under the
control of the two HDACs examined. Within this level of
complexity also the MITR isoform can be included. In
fact, although MITR has been described as a transcrip-
tional repressor, it contains16 aa of unknown function at
the carboxy-terminus that differ from the HDAC9 canoni-
cal isoform (55). Perhaps this complex, when assembled on
the HDAC9 promoter, could impair the manifestation of a
full repressive state.
A third level of complexity is obtained by a locus-
dependent influence of a specific class IIa HDAC. In fact,
even though a region is characterized by the co-presence
ofMEF2D/HDAC4/HDAC9 complexes, frequently only a
family member plays an active role in the epigenetic regula-
tion. We define this phenomenon as the dominant positional
effect of a specific class IIa HDAC. An example is the inter-
genic region distal from the AHRGEF28 locus. This region
shows features of an enhancer and through chromatin loop-
ing could regulate the expression of ENC1. Although both
HDAC4 and HDAC9 bind this region, only the knock-out
of HDAC9 increases H3K27ac levels at the enhancer and
promoter sites thus augmenting ENC1 expression.
In general, the paucity of promoter regions bound by
HDAC9 suggests that this HDAC is recruited by MEF2D
or by alternative TFs to repress gene expression princi-
pally from distal regulative elements showing features of en-
hancers.
Another important difference marks HDAC9 with re-
spect to HDAC4. HDAC9 very rarely binds the genome in
open chromatin regions, as defined by H3K27ac. This data
indicates that HDAC9 typifies stably repressed chromatin
domains while HDAC4 influences more dynamic genomic
regions, or could suggest that HDAC4 acts as the priming
pioneering repressive factor for HDAC9.
Finally, a further layer of regulation is represented
by MEF2D complexes that are not recognized by both
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should be taken into account, the demonstration that
MEF2A andMEF2D can still sustain transcription on spe-
cific loci discourages the HDAC5 hypothesis (6). On these
loci,MEF2D acts positively by promoting the transcription
of the associated genes. This evidence demonstrates that
MEF2D has the capability to selectively escape the surveil-
lance of class IIa HDACs on some well-defined genomic re-
gions.
Despite the less numerous genomic binding sites and re-
duced number of genes under its influence, HDAC9 shows
a strong impact on LMS cells proliferation. Cells deprived
of HDAC9 show a higher apoptotic index that limits their
prolonged maintenance in tissue culture. In this respect, we
speculate that a certain degree of transcriptional hetero-
geneity, observed among the different HDAC9−/− clones,
could reflect adaptive mechanisms that cells engage to sur-
vive the strong apoptotic pressure.
FAS up-regulation and the activation of the extrinsic
pathway are responsible for the increased apoptotic pres-
sure. Cytokines such as TNF-, IL12 and IFN can sustain
FAS transcription through the engagement of NF-kB, SP1,
STAT1 and IRF8 (56–60). Also TP53 family members are
involved in FAS transcription (61,62).
We could not find HDAC9 and MEF2D binding sites
at the promoter region of FAS. However H3K27ac was in-
creased after the deletion of HDAC9, both at the promoter
and at a distal site within the subTAD. This distal region
can undergo looping with the FAS promoter.
How HDAC9 could influence H3K27 acetylation at the
FAS/ACTA2 locus is mysterious. It could operate through
a distal enhancers or indirectly by controlling the expres-
sion of specific TFs. In fact, approx. 10% of the genes re-
pressed by HDAC9 encode for TFs or epigenetic regulators
and among them SMAD3 has been demonstrated to up-
regulate FAS transcription (63). Although FAS is a key el-
ement of the increased apoptotic response in HDAC9 defi-
cient SK-UT-1 cells,MEF2 are pleiotropic TFs and in other
contexts their pro-survival activities can be mediated by the
regulation of different pro-survival or pro-death genes (64–
66).
The impact of HDAC9 on LMS cells proliferation/su
rvival is not limited to SK-UT-1 cells. DMR cells sim-
ilarly overexpress HDAC9 and HDAC9 downregulation
up-regulates FAS levels and triggers apoptosis in DMR
cells too. We are confident that the repressive influence of
HDAC9 on FAS transcription is a critical event for LMS
survival/aggressiveness, as proved by the anti-correlation
observed in tumors.
CONCLUSIONS
LMS are aggressive cancers, local recurrence and metas-
tasis develop in approximately 40% of cases, which drasti-
cally reduce survival (19,34,47–49). Under these conditions
available therapies are largely ineffective and the identifi-
cation of new therapeutic targets is mandatory. Our stud-
ies point to class IIa HDACs and HDAC9 in particular
as interesting targets to revitalize the extrinsic apoptotic
pathway. Furthermore, the simultaneous up-regulation of
chemokines, cytokines and secreted factors, exemplified by
CXCL1, IL8, THBS1 andCYR61, after HDAC9 depletion,
can sustain FAS-induced apoptosis and the action of the
immune system for a better elimination of the neoplastic
cells (67–69). This represent a strong incitement to evaluate
HDAC9 inhibitors as possible onco-immunological drugs.
Finally, we are confident that our deep investigation and de-
scription of the genomic preferences of MEF2D-HDAC4-
HDAC9 complexes can fit to other models and help re-
searchers in finding a genetic and epigenetic explanation to
the pleiotropic actions of MEF2 TFs.
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